Cutler Group’s Corvus Pharmaceuticals CRVS Stock Holding History

Cutler Group’s Portfolio CRVS Stock Details CRVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-233,400	Closed	-$38K	–	5452
2021 Q3	$38K	Buy	+233,400	New	+$691K	﹤0.01%	2748

Other funds holding CRVS

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

ASP

Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Cutler Group's CRVS Position: Q2 2022 in Review

Cutler Group sold out of Corvus Pharmaceuticals (CRVS) in Q2 2022, closing a stake of 4,700 shares — an estimated $7K sold.

Cutler Group first reported a position in CRVS in Q3 2020 and held it in 7 quarters. The position peaked at $75K in Q3 2021. 47 funds tracked by Wall St. Rank hold CRVS as of Q2 2022.

Cutler Group reported no remaining Corvus Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
Cutler Group sold 4,700 Corvus Pharmaceuticals shares in Q2 2022, an estimated $7K.
Cutler Group first reported a position in Corvus Pharmaceuticals in Q3 2020 and held it in 7 quarters.
Cutler Group's Corvus Pharmaceuticals position peaked at $75K in Q3 2021.
47 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2022.

Based on Cutler Group's 13F filing for Q2 2022, filed 4 Aug 2022.